Literature DB >> 25772243

GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.

G Maric1,2, M G Annis1,2, Z Dong1,2, A A N Rose1,2, S Ng1,3, D Perkins1,3, P A MacDonald1,2, V Ouellet1,2, C Russo1,2, P M Siegel1,2,3,4.   

Abstract

Glycoprotein nmb (GPNMB) promotes breast tumor growth and metastasis and its expression in tumor epithelium correlates with poor prognosis in breast cancer patients. Despite its biological and clinical significance, little is known regarding the molecular mechanisms engaged by GPNMB. Herein, we show that GPNMB engages distinct functional domains and mechanisms to promote primary tumor growth and metastasis. We demonstrate that neuropilin-1 (NRP-1) expression is increased in breast cancer cells that overexpress GPNMB. Interestingly, the GPNMB-driven increase in NRP-1 expression potentiated vascular endothelial growth factor signaling in breast cancer cells and was required for the growth, but not metastasis, of these cells in vivo. Interrogation of RNAseq data sets revealed a positive correlation between GPNMB and NRP-1 levels in human breast tumors. Furthermore, we ascribe pro-growth and pro-metastatic functions of GPNMB to its ability to bind α5β1 integrin and increase downstream signaling in breast cancer cells. We show that GPNMB enhances breast cancer cell adhesion to fibronectin, increases α5β1 expression and associates with this receptor through its RGD motif. GPNMB recruitment into integrin complexes activates Src and Fak signaling pathways in an RGD-dependent manner. Importantly, both the RGD motif and cytoplasmic tail of GPNMB are required to promote primary mammary tumor growth; however, only mutation of the RGD motif impaired the formation of lung metastases. Together, these findings identify novel and distinct molecular mediators of GPNMB-induced breast cancer growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772243     DOI: 10.1038/onc.2015.8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Authors:  Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L Harris; Jan G M Klijn; John A Foekens; Fatima Cardoso; Martine J Piccart; Marc Buyse; Christos Sotiriou
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

2.  Expression of class 3 semaphorins and their receptors in human breast neoplasia.

Authors:  Carolyn A Staton; Lucy A Shaw; Manoj Valluru; Leslie Hoh; Ivan Koay; Simon S Cross; Malcolm W Reed; Nicola J Brown
Journal:  Histopathology       Date:  2011-08       Impact factor: 5.087

3.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Authors:  Johanna Bendell; Mansoor Saleh; April A N Rose; Peter M Siegel; Lowell Hart; Surendra Sirpal; Suzanne Jones; Jennifer Green; Elizabeth Crowley; Ronit Simantov; Tibor Keler; Thomas Davis; Linda Vahdat
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 4.  Integrin control of tumor invasion.

Authors:  Dara S Missan; Michael DiPersio
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

5.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer.

Authors:  Josie Ursini-Siegel; W Rod Hardy; Dongmei Zuo; Sonya H L Lam; Virginie Sanguin-Gendreau; Robert D Cardiff; Tony Pawson; William J Muller
Journal:  EMBO J       Date:  2008-02-14       Impact factor: 11.598

Review 6.  Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).

Authors:  Christos Vaklavas; Andres Forero
Journal:  BioDrugs       Date:  2014-06       Impact factor: 5.807

7.  The AP-3-dependent targeting of the melanosomal glycoprotein QNR-71 requires a di-leucine-based sorting signal.

Authors:  R Le Borgne; N Planque; P Martin; F Dewitte; S Saule; B Hoflack
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

8.  Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice.

Authors:  Matilda H-C Sheng; Jon E Wergedal; Subburaman Mohan; Mehran Amoui; David J Baylink; K-H William Lau
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

9.  A complex containing LPP and α-actinin mediates TGFβ-induced migration and invasion of ErbB2-expressing breast cancer cells.

Authors:  Elaine Ngan; Jason J Northey; Claire M Brown; Josie Ursini-Siegel; Peter M Siegel
Journal:  J Cell Sci       Date:  2013-02-27       Impact factor: 5.285

10.  Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Authors:  Gordana Maric; April An Rose; Matthew G Annis; Peter M Siegel
Journal:  Onco Targets Ther       Date:  2013-07-09       Impact factor: 4.147

View more
  30 in total

Review 1.  Neuropilin Functions as an Essential Cell Surface Receptor.

Authors:  Hou-Fu Guo; Craig W Vander Kooi
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

Review 2.  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors:  Noam Pondé; Philippe Aftimos; Martine Piccart
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

3.  C-reactive protein binds to integrin α2 and Fcγ receptor I, leading to breast cell adhesion and breast cancer progression.

Authors:  E-S Kim; S Y Kim; M Koh; H-M Lee; K Kim; J Jung; H S Kim; W K Moon; S Hwang; A Moon
Journal:  Oncogene       Date:  2017-08-28       Impact factor: 9.867

Review 4.  Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  FASEB J       Date:  2020-05-23       Impact factor: 5.191

Review 5.  Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.

Authors:  Hassan Yousefi; Mousa Vatanmakanian; Mojdeh Mahdiannasser; Ladan Mashouri; Nikhilesh V Alahari; Mohammad Rafiee Monjezi; Shahrzad Ilbeigi; Suresh K Alahari
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

Review 6.  Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.

Authors:  Manisha Taya; Stephen R Hammes
Journal:  Steroids       Date:  2017-10-31       Impact factor: 2.668

7.  A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells.

Authors:  Danh D Truong; Alexander Kratz; Jin G Park; Eric S Barrientos; Harpinder Saini; Toan Nguyen; Barbara Pockaj; Ghassan Mouneimne; Joshua LaBaer; Mehdi Nikkhah
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

Review 8.  Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.

Authors:  Kevin M Budge; Matthew L Neal; Jason R Richardson; Fayez F Safadi
Journal:  Mol Neurobiol       Date:  2017-08-30       Impact factor: 5.590

9.  Glycoprotein non-metastaticmelanoma protein B promotes glioma motility and angiogenesis through the Wnt/β-catenin signaling pathway.

Authors:  Gang Bao; Ning Wang; Ruichun Li; Gaofeng Xu; Peijun Liu; Baixiang He
Journal:  Exp Biol Med (Maywood)       Date:  2016-06-21

10.  Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients.

Authors:  Masato Kobayashi; Jin-Sung Chung; Muhammad Beg; Yull Arriaga; Udit Verma; Kevin Courtney; John Mansour; Barbara Haley; Saad Khan; Yutaka Horiuchi; Vijay Ramani; David Harker; Purva Gopal; Farshid Araghizadeh; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Clin Cancer Res       Date:  2018-07-26       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.